Drugs / SBK2-ICG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07438860 | Mar → Nov 2026 expected | brain cancer, glioma | Tiffany Hodges | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SBK2-ICG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07438860 ↗ |
| Modality | Diagnostic / imaging agent | “The purpose of this study is to see whether a drug called SBK2-ICG can be used to locate the true outline or "edges" of the tumor.” NCT07438860 ↗ |
| Route | Intravenous | “Participants will receive a single intravenous (IV) dose of SBK2-ICG one hour prior to their craniotomy (brain surgery).” NCT07438860 ↗ |